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Abstract Hypermethylation of the MGMT gene promoter
and mutation of the TP53 tumor-suppressor gene are fre-
quently present in diffuse astrocytomas. However, there is
only anecdotal information about MGMT methylation sta-
tus and TP53 mutations during progression of low-grade
diffuse astrocytoma (AII) to anaplastic astrocytoma (AIII)
and secondary glioblastoma (sGB). In this study biopsy
specimens from 51 patients with astrocytic tumors with
radiologically proved progression from low to high-grade
malignancy were investigated for the presence and con-
sistency of MGMT promoter hypermethylation and TP53
mutations. For 27 patients biopsy samples both of primary
tumors and their recurrences were available. For the other
24 patients histology of either the low-grade lesion or the
high-grade recurrence was available. It was found that
MGMT promoter hypermethylation and TP53 mutations
are both frequent and early events in the progression of
astrocytomas and that their status is consistent over time.
No correlation was found between MGMT methylation
status and the presence of TP53 mutations. In addition, no
correlation was found between MGMT promoter hyper-
methylation and the type of TP53 mutations. These results
argue against the putative TP53 G:C[A:T transition
mutations suggested to occur preferentially in MGMT
hypermethylated tumors.
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Introduction
Low-grade diffuse astrocytomas (WHO grade II; AII) are
slowly growing tumors with a peak incidence in young
adults. They diffusely inﬁltrate the normal brain and have
an intrinsic tendency to progress to greater malignancy, i.e.
anaplastic astrocytoma (WHO grade III; AIII) and sec-
ondary glioblastoma (WHO grade IV; sGB). Currently
available treatment strategies, for example tumor resection,
radiotherapy, and/or chemotherapy are only partially effec-
tive and most patients develop recurrent or progressive
disease. For development of new treatment strategies,
identiﬁcation of genetic alterations associated with patho-
genesis, progression, and treatment response of these slow-
growing tumors is necessary.
The tumor-suppressor gene TP53 on chromosome
17p13.1 encodes a key transcription factor involved in
several cellular mechanisms including growth arrest, DNA
repair, and induction of apoptosis. Mutations in the TP53
gene have been reported as early and frequent events in
sGB and their precursor lesions [1, 2] whereas de-novo
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DOI 10.1007/s11060-010-0274-xprimary glioblastomas reportedly lack TP53 mutations or
acquire them late in tumorigenesis [3, 4]. However, the
presence of TP53 mutations in the progression of AII to
AIII and sGB has mostly been determined in investigations
of series of astrocytic tumors with different grades of
malignancy without following individual tumors for their
tumorigenesis [5, 6]. In some but not all studies on AII, the
TP53 mutation was found to be an independent unfavor-
able predictor of survival and/or malignant transformation
[3, 7–9]. Other genetic aberrations in the TP53 pathway,
for example MDM2 ampliﬁcation and p14
ARF deletion or
hypermethylation are also frequently observed in low-
grade diffuse astrocytomas [7, 10, 11].
Over the last decade, epigenetic silencing of the
O
6-methylguanine-methyltransferase (MGMT) gene by
promoter hypermethylation has been found to be associ-
ated with chemosensitivity of a variety of tumor types,
including gliomas [12–16]. The MGMT gene is located
on chromosome band 10q26 and encodes for O
6-alkyl-
guanine-DNA-alkyltransferase (AGT), a repair enzyme
that removes promutagenic alkylating DNA adducts from
the O
6 position of guanine, an important target of alkyl-
ating and methylating agents. Lack of MGMT repair
capacity contributes to the genesis and progression of
human cancers, because it leads to the accumulation of
DNA mutations and chromosomal instability [12, 14, 17].
During chemotherapy with alkylating and methylating
agents the primary cell mechanism inducing chemoresis-
tence is the demethylating activity of AGT, which removes
the alkyl adducts. The absence of MGMT activity can
therefore be used as a predictor of response for patients
treated with alkylating chemotherapeutic agents. High-
grade gliomas, in particular glioblastomas, with hyperme-
thylated MGMT promoters proved to be more sensitive to
chemotherapeutic agents, including temozolomide (TMZ),
resulting in an overall survival beneﬁt for these patients
[13, 15, 18–20].
Apart from the predictive value, the MGMT promoter
hypermethylation status has been associated with shorter
progression-free survival in AII [21, 22]. In several reports
an association between MGMT promoter hypermethylation
and an increased frequency of TP53 mutations, with pre-
dominance of G[Ao rC [T transitions (G:C[A:T transition
mutations), especially at CpG sites, has been mentioned
[11, 21, 23–25]. Further, in a recent population-based study
of glioblastomas a higher frequency of TP53 G:C[A:T
transition mutations in tumors with MGMT promoter
hypermethylation (25%) than in glioblastomas without
MGMT methylation (16%, P = 0.0385) was reported [26].
However, information about MGMT promoter hyperme-
thylation or TP53 mutation during astrocytoma progression
is sparse [11, 23]. The objective of this study was to
investigate the association of MGMT promoter methylation
status and TP53 mutations and to determine the consistency
of these molecular characteristics over time, in a series of
diffuse astrocytomas and their recurrences.
Materials and methods
Patients and tumor samples
Archival routine formalin-ﬁxed and parafﬁn-embedded
(FFPE) tumor tissues were collected from 51 patients
diagnosed with:
(1) an AII at the time of the ﬁrst operation; or
(2) a histopathology of high-grade astrocytic tumor after
a wait and see period of at least 1.5 years and a lesion
on MR scan without contrast enhancement (clinically
regarded as an original low-grade astrocytic tumor).
Glioma recurrences were diagnosed by contrast enhance-
ment on MR scans, with or without clinical symptoms,
and/or histopathology of tissue biopsies. For 27 patients
tumor tissue was available both from the ﬁrst operation
and from the operation for the recurrence. For 17 patients
only tumor tissue from the ﬁrst operation was available
and for seven patients only tissue from the second sur-
gery was available (Table 1). Hematoxylin and eosin
(H&E)-stained tissue sections from all tumors were
reviewed by an independent neuropathologist (JMK) in
accordance with the latest WHO guidelines for typing and
grading [27].
All patients received radiation therapy after surgery for
the primary tumor. Four of the 27 patients (Table 1; cases
21, 22, 29, and 32) were treated with alkylating chemo-
therapy (procarbazine, lomustine, and vincristine) between
the operations for the primary and recurrent tumors. All
patients were treated with temozolomide after the opera-
tion for the recurrent tumor. By the end of this study all
patients had died. The median follow-up time was 65.5
months.
The archival tissue samples were used in accordance
with the code of conduct for appropriate secondary use of
tissue: ‘‘Proper Secondary Use of Human Tissue’’ estab-
lished by the Dutch Federation of Medical Scientiﬁc
Societies (http://www.federa.org).
DNA extraction
H&E-stained sections from the available FFPE tissue
blocks were used by the neuropathologist (JMK) to select
parts for DNA extraction. DNA was isolated by standard
procedures from selected tissue fragments containing a
high percentage tumor cells and, when possible, from
fragments of normal tissue [28].
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123Methylation-speciﬁc multiplex ligation-dependent
probe ampliﬁcation (MS-MLPA) for MGMT
The MS-MLPA probe mix used (ME011; MRC Holland,
Amsterdam, The Netherlands) includes 21 probe sequences
containing an HhaI recognition site, which yields infor-
mation about the methylation status of the target sequen-
ces. In addition, eight control probe sequences not affected
by the methylation-sensitive restriction enzyme HhaI
digestion are used. The probes containing an HhaI recog-
nition site should only generate a signal if the DNA target
is methylated and cannot be digested. The probe mix was
developed to detect CpG island methylation of six mis-
match repair genes and includes three speciﬁc probes for
semiquantitative hypermethylation detection of the MGMT
promoter region. This MS-MLPA assay for MGMT pro-
moter hypermethylation of gliomas was performed as
described by Jeuken et al., with minor modiﬁcations [29].
For fragment analysis, PCR products were separated by
capillary gel electrophoresis (ABI Prism 3130xl; Applied
Biosystems, Foster City, CA, USA) and quantiﬁed by use
of GeneMarker software version 1.7 (SoftGenetics, State
College, PA, USA).
MS-MLPA data analysis
The MS-MLPA results were normalized by dividing the
peak height for each MGMT probe signal by the mean peak
height for the eight control fragments within the same
sample. To estimate the fraction of methylated MGMT
promoter DNA, normalized values of each MGMT probe of
digested DNA samples were divided by normalized values
of corresponding undigested DNAs. Methylation analyses
were performed in duplicate and the average ratios of both
experiments for each probe were calculated. For the pro-
moter hypermethylation detection of MGMT, we used the
MGMT2 probe from the probe mix only. This probe is
located within the widely used CpG island region for
MGMT promoter hypermethylation detection by methyla-
tion-speciﬁc PCR (MS-PCR), and hypermethylation of this
region has been found to be an independent predictor of the
response of gliomas to TMZ [13, 15, 19, 20].
Preliminary comparison of the widely used MS-PCR
and the MGMT2 probe analyses demonstrated concordant
results (not shown). Also, in our hands, the MGMT2 probe
also resulted in better assay reproducibility (Spearman’s
rho 0.658, P\0.001) than the two other MGMT probes
(MGMT1 probe Spearman’s rho 0.448; P = 0.032 and
MGMT3 probe Spearman’s rho 0.431; P = 0.040). Cell
lines were used as positive (TE-4, OEC33, FLO-1, SW620)
or negative (TE-1, TE-5, TE-13, TE-14, SK-GT-2, BE-3,
ESO51) controls for evaluation of MGMT promoter
methylation. When the MGMT digested/MGMT undigested
ratio of probe MGMT2 is below 0.30 the MGMT promoter
fragment is regarded as non-methylated, as described pre-
viously for MS-MLPA assays [30, 31].
Mutation analysis of TP53
Tumor samples from each patient were screened for TP53
mutations in exons 4–9, including intron–exon boundaries,
by polymerase chain reaction (PCR) followed by bi-
directional direct DNA sequencing using the M13-tailed
primer method. Intronic primer sets for PCR ampliﬁcation
are shown in Table 2A. PCR products were generated in a
15-ll reaction mixture containing 1.0 ll DNA solution,
10 lmol of each primer, 25 mM MgCl2, 10 mM dNTPs,
and 1U Taq polymerase (Promega, Madison, WI, USA).
The PCR reaction was performed using a thermocycler
(Biometra, Go ¨ttingen, Germany) with an initial denaturing
step (95C) for 3 min, followed by 35 cycles consisting of
denaturing (95C) for 30 s, annealing (60C) for 45 s, and
extension (72C) for 45 s. After the ﬁnal cycle, an exten-
sion period of 10 min at 72C was performed. The PCR
products (5 ll) were digested with 1 ll exonuclease I
(ExoSAP-IT; USB, Cleveland, OH, USA) at 37C for
30 min followed by inactivation of the enzyme at 80C for
15 min. The PCR products were sequenced on an ABI
Prism 3130xl genetic analyzer using the ABI Prism BigDye
Terminator v3.1 kit (both from Applied Biosystems).
Samples were analyzed by use of Mutation Surveyor
software package version 3.2 (SoftGenetics, State College,
PA, USA) and compared with the public sequence in
GenBank (NM_000546).
Loss of heterozygosity (LOH) analysis of the TP53
locus (17p13)
Five highly polymorphic microsatellite markers located on
chromosome 17p13 (D17S1353, D17S1866, D17S1566,
D17S786, and D17S520) were used for LOH analysis.
Microsatellites were ampliﬁed with ﬂuorescence-labeled
forward and unlabeled reverse primers (Table 2B).
Because normal DNA from non-neoplastic tissues was not
available for most of the tumor samples, allelic losses were
determined by analysis of the allelic patterns and by inte-
gration of data from multiple highly polymorphic markers,
as described elsewhere [32]. LOH analysis was performed
using the ABI Prism 3130xl Genetic Analyzer (Applied
Biosystems) and the GeneMarker software package version
1.7 (SoftGenetics).
Immunohistochemistry (IHC) for p53
IHC for p53 was performed on 4-lm sections of routine
FFPE tissues. Brieﬂy, sections were deparafﬁnized in
410 J Neurooncol (2011) 101:405–417
123xylene and hydrated through descending ethanol gradients.
Endogenous peroxidase was inactivated by treatment with
3% H2O2 in phosphate-buffered saline (PBS). Antigen
retrieval was accomplished by boiling the sections for
15 min in 10 mmol/l Tris–EDTA, pH 9.0 in a microwave
oven. The sections were incubated for 1 h at room tem-
perature with mouse monoclonal antibody DO-7 against
p53 protein (Dako, Glostrup, Denmark) at 1:50 dilution.
After rinsing in PBS, immunoreactivity was visualized
using the Envision kit (Dako). The sections were subse-
quently counterstained with Mayer hematoxylin. Although
the DO-7 antibody binds to both normal and mutant p53
protein, in general, normal levels of wild-type p53 protein
are too low to be detected by immunohistochemistry. In
each section, the number of clearly positive cells out of
1000 cells was counted and[10% was regarded as positive
[33].
Statistical analysis
Correlation coefﬁcients were calculated by use of Student’s
t-test and Fisher’s exact test. Data were regarded as sta-
tistically signiﬁcant at P\0.05.
Results
The results from histopathological review and molecular
analysis are summarized in Table 1. After molecular
investigation of the 27 cases of paired primary tumors and
recurrences (Table 1, cases 18–44) four cases with
different TP53 mutations and/or reverse LOH patterns were
regarded as two clonally independent entities (cases 18, 34,
36, and 44). The strongest indication of clonally indepen-
dent entities is the ﬁnding of speciﬁc molecular aberrations
in the primary tumors which are not found in the recur-
rences. In case 43 neither a TP53 mutation nor LOH was
found in the primary tumor whereas in the recurrence a
TP53 mutation and LOH were detected. This could indicate
clonally independent tumors. However, because no molec-
ular aberrations were detected in the primary tumor and
because of the long period of time between occurrence of
the primary lesion and recurrence (146 months) we regard
case 43 as more likely to be clonally related tumors with
generation and clonal selection of the aberrations during
the long time interval between both tumors.
Patients and tumor histology
According to central review, 34 of 44 (77%) primary
tumors were diffuse astrocytomas of WHO grade II (AII); 6
of 44 (14%) were anaplastic astrocytomas (AIII), and 3 of
44 (7%) were glioblastoma (GB). One primary tumor
was diagnosed as an anaplastic mixed oligoastrocytoma
(OAIII). Of the recurrent tumors 10 of 34 (29%) were still
AII; 5 of 34 (15%) had progressed to AIII; and 15 of 34
(44%) became secondary glioblastomas (sGBs). Two
recurrent tumors were diagnosed as anaplastic mixed oli-
goastrocytomas (OAIII), one as anaplastic oligodendrogli-
oma (OIII), and one as low-grade oligoastrocytoma (OAII).
In all tumors with an oligodendroglial component found by
Table 2 Primer sets for TP53 mutation analysis and LOH analysis of the TP53 Locus
Exon Size (bp)
a Forward primer Reverse primer
A Nucleotide sequences of primers used for TP53 mutation analysis
Exon 4A 300 50-CTGGTAAGGACAAGGGTTGG-30 50-GATGACAGGGGCCAGGAG-30
Exon 4B 249 50-AGATGAAGCTCCCAGAATGC-30 50-GATACGGCCAGGCATTGAAG-30
Exon 5A 222 50-TGCTGCCGTCTTCCAGTTGC-30 50-CTCACAACCTCCGTCATGTG-30
Exon 5B 197 50-CAGCTGTGGGTTGATTCCAC-30 50-TGAGGAATCAGAGGCCTG-30
Exon 6 263 50-TCAGATAGCGATGGTGAGCA-30 50-GCCACTGACAACCACCCTTA-30
Exon 7 215 50-CGCACTGGCCTCATCTTG-30 50-AGGGGTCAGAGGCAAGCAGA-30
Exon 8 248 50-GGGACAGGTAGGACCTGATTT-30 50-GCATAACTGCACCCTTGGTC-30
Exon 9 232 50-GGAGACCAAGGGTGCAGTTA-30 50-CCCCAATTGCAGGTAAAACA-30
B Nucleotide sequences of primers used for LOH analysis of the TP53 Locus
D17S520 142 50-GGAGAAAGTGATACAAGGGA-30 50-TAGTTAGATTAATACCCACC-30
D17S786 167 50-TACAGGGATAGGTAGCCGAG-30 50-GCTGTGAGTCCCAAAAGAGG-30
D17S1353 122 50-ATTCCCACTGCCACTCCTTG-30 50-CAGCTGAGGGATACTATTCAG-30
D17S1566 189 50-AAAGATCCTTATTGCCACTTTACTG-30 50-CTCTTACCTTGCTGGTGAGATTG-30
D17S1866 175 50-TGGATTCTGTAGTCCCAGG-30 50-GGTTCAAAGACAACTCCCC-30
a Amplicon sizes based on the UCSC Genome Browser (http://genome.ucsc.edu)
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123central review, loss of chromosome 1p and/or 19q was
excluded in these cases (results not shown).
Of the 27 cases of which both the primary and recurrent
tumor were investigated, 23 cases were regarded as having
clonally related tumors and four cases clonally unrelated
tumors, on the basis of molecular results. Thirteen of 23
(57%) clonally related tumor pairs showed histological
progression of malignancy grade. In nine cases (39%) the
tumor histology had not progressed in malignancy grade. In
one case the histology of the recurrence seemed to indicate
lower malignancy grade than the primary tumor; this was
attributed to sampling error in the recurrence (Table 1, case
30). For the 23 paired, clonally related histological samples
the mean interval between surgery for the primary tumor
and recurrence was 45.1 ± 35.2 months (range 8–146
months). The mean interval between surgery for primary
and recurrent tumors of those cases in which the histology
of the ﬁrst biopsy had not progressed in malignancy grade
was 50.0 months; for the tumors in which histological
progression had occurred the mean interval was
41.3 months (Student’s t-test, P = 0.57).
Hypermethylation analysis of the MGMT promoter
Seventy-eight tumor samples were available for MGMT
promoter hypermethylation and TP53 mutation analysis
(viz.: 21 samples from patients for whom only the ﬁrst
specimens were available; 54 samples from 27 patients for
whom both the ﬁrst and second surgery tissue samples were
available; and three samples from patients for whom only
the second tumor specimens were available). Results
showing MGMT promoter hypermethylation by MS-MLPA
were obtained for 70 of 78 (90%) of the (routine FFPE)
tumor tissues (Table 1). MGMT promoter hypermethyla-
tion was identiﬁed in 39 of these 70 (56%) tumor samples.
There was no relationship between tumor grade (viz., AII,
AIII or sGB) and methylation status (53% vs. 64% vs. 56%
hypermethylated, respectively). For 20 of 23 clonally
related tumor pairs MGMT promoter hypermethylation
results were obtained from both tumors. In 18 of 20 cases
(90%), primary and recurrent tumors had a similar MGMT
promoter methylation status (nine tumor pairs hyperme-
thylated; nine tumor pairs not methylated). For two pairs of
related tumors a change of MGMT methylation status
between the primary and the recurrent tumors was found.
There was no relationship between change in MGMT
methylation status and intervening treatment with alkylat-
ing chemotherapy. Of the four cases with clonally
independent tumors, one had different MGMT hyperme-
thylation status, two had identical MGMT hypermethyla-
tion status, and for one case no data could be obtained from
the second tumor.
TP53 mutation analysis and p53 expression
TP53 exon 4–9 DNA sequence data were obtained from 74
of 78 (95%) tumor samples. Four samples had inferior
DNA quality resulting in no reliable sequencing data. TP53
mutation analysis revealed mutations in 40 of the 52 (77%)
independent cases. In 35 of these 40 (88%) independent
cases one mutation, and in 5 of 40 (13%) cases two TP53
mutations within the same tumor sample were detected.
TP53 mutations were detected in 28 of 41 (68%) tumors
with histological diagnosis of AII, in 10 of 10 (100%) AIII,
and in 13 of 18 (72%) GB (Table 1). Mutation of TP53 was
found in 17 of 23 (74%) tumor pairs (primary tumors and
their recurrences) regarded as clonally related. In three of
these 17 tumor pairs two different TP53 mutations in the
same tumor sample were detected and these mutations all
remained present in the recurrent tumors. Two tumor pairs
had TP53 mutations in the recurrent tumors only, and in
one case TP53 mutation was only found in the primary
tumor. In two tumor pairs the mutation in the primary
tumor differed from that in the recurrence. In ﬁve tumor
pairs TP53 mutations were not found in either the primary
or recurrent tumor, and in one tumor pair no sequence data
were obtained.
A total of 45 TP53 mutations were detected in 40 of 55
independent tumors. Three mutations were found in TP53
exon 4, ﬁfteen in exon 5, six in exon 6, four in exon 7,
fourteen in exon 8, and three in exon 9. A not previously
reported in-frame duplication of 18 nucleotides (codon
107–112) in exon 4 was found in one patient (Table 1,
case 2). Of all the TP53 mutations identiﬁed in independent
cases, 20 of 45 (44%) were G:C[A:T transition mutations;
of these, 18 of 20 (90%) were located atCpG sites. Of the 25
not G:C[A:T transition mutations only three mutations
(12%) were located at CpG sites. The two G:C[A:T tran-
sition mutations that were not located at CpG sites were
found in exon 9, the exon of TP53 without CpG sites.
Positive immunohistochemistry for p53 was associated
with either mutation of the TP53 gene (Fisher’s exact test,
P = 0.02) or LOH of the TP53 locus (Fisher’s exact test,
P = 0.02) or both (Fisher’s exact test, P\0.001). In ﬁve
of eight tumor samples without p53 expression neither
TP53 mutation nor LOH was found. The remaining three
samples without p53 expression had TP53 frameshift
mutations and, in accordance with this type of mutation,
p53 expression was absent.
LOH analysis of the TP53 locus (17p13)
All 78 tumor samples in the study were informative for at
least two of ﬁve microsatellite markers on chromosome
17p13. In 38 of 48 (78%) tumors with a single TP53
mutation, LOH of the TP53 locus was found. In all tumors
412 J Neurooncol (2011) 101:405–417
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17p13 was observed. LOH of the TP53 locus was found in
ﬁve out of 13 (38%) AII without TP53 mutation and in four
out of seven (57%) recurrent tumors without TP53 muta-
tion. The allelic loss pattern was different between three
tumor pairs in which LOH was found in the recurrent
tumor only. Further, reverse allelic loss of the primary and
recurrent tumor was detected in three patients. One of these
had a different mutation in each tumor whereas two
patients had a mutation in only one of the tumor pairs.
Correlation between MGMT promoter
hypermethylation and TP53 mutations
There was no signiﬁcant correlation between MGMT pro-
moter hypermethylation and TP53 mutation (Fisher’s exact
test, P = 0.77; Table 3). In addition, there was no signif-
icant correlation between MGMT promoter hypermethyla-
tion and the presence of G:C[A:T transition mutations in
TP53. G:C[A:T transition mutations were found in 10 of
21 (48%) independent tumors with a hypermethylated
MGMT promoter and a TP53 mutation, and in nine of 16
(56%) MGMT promoter unmethylated tumors with a TP53
mutation (Fisher’s exact test, P = 0.80; Table 3).
Discussion
In this study we demonstrated that MGMT promoter hy-
permethylation and TP53 aberrations are early and frequent
events in the progression of astrocytomas and that both are
largely consistent over time. In addition, we did not ﬁnd a
correlation between MGMT promoter methylation status
and TP53 mutations. These results argue against the
putative TP53 G:C[A:T transition mutations which have
been suggested to occur preferentially in MGMT hyper-
methylated tumors.
MGMT promoter hypermethylation
No data on the MGMT promoter methylation status during
astrocytic tumor progression have yet been reported. In this
study, we showed that MGMT promoter hypermethylation
is not limited to high-grade astrocytomas but should be
regarded as an early and frequent event in primary AII and
AIII, which remains present during tumor progression.
MGMT promoter hypermethylation was found in 58% of
primary AII, consistent with frequencies reported by
Nakamara et al., Watanabe et al., and Nakasu et al. [11, 23,
34], who demonstrated MGMT promoter hypermethylation
by MS-PCR or immunohistochemistry in 48, 63, and 68%
of AII, respectively.
Discrepancies between results from immunohistochem-
istry and from PCR experiments should be taken into
consideration. We found concordance in MGMT promoter
hypermethylation status between primary and recurrent
tumors in 18 of 20 (90%) clonally related tumor pairs. The
remaining two cases demonstrate that MGMT promoter
hypermethylation may change during astrocytoma pro-
gression, e.g., by reversibility of the hypermethylation,
clonal selection of methylated or unmethylated subclones,
or by loss of the hypermethylated MGMT allele. No rela-
tionship between a change in MGMT promoter methylation
status and intervening treatment with alkylating chemo-
therapy was revealed. Recently, Brandes et al. reported
their study on the stability of MGMT methylation status in
a series of 38 patients with a glioblastoma and second
surgery for recurrence. MGMT methylation status changed
in 37% of the patients and more frequently in methylated
than in unmethylated tumors [35].
TP53 mutations
With regard to the analyses of molecular aberrations in
tumors it must be considered that, because of the general
procedures used, technically only aberrations present in
most of the cells from which the DNA was isolated (i.e.
clonal aberrations) will be detected. Tumors are composed
of neoplastic and non-neoplastic (normal) cells and it is
generally accepted that the neoplastic cells, in contrast with
normal cells, harbor clonal molecular aberrations. DNA
isolated from a part of the tumor is composed of the DNA
of the neoplastic cells and the DNA of the normal cells.
These facts imply that when a speciﬁc molecular aberration
is reliably identiﬁed in the DNA sample isolated from the
tumor, this DNA sample is retrieved from a part of the
tumor composed of a high percentage of clonal neoplastic
cells. Admixture of a high percentage of normal cells or the
presence of heterogeneous (with regard to the determined
aberration) neoplastic cell populations would have masked
the aberration and prevented its detection.
Table 3 Correlation between MGMT promoter hypermethylation
status and TP53 mutation status
MGMT
hypermethylated
(n = 29)
a
MGMT not
hypermethylated
(n = 20)
P value
TP53 mutated 21 16 0.77
G:C[A:T mutation 10 9 0.80
G[A transition 7 2
At CpG site 7 2
C[T transition 3 7
At CpG site 3 5
TP53 not mutated 7 4
a Case 10: no data on TP53 mutation could be obtained
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detected in the astrocytic tumors in this study is in accor-
dance with the highest frequencies reported in the literature
[1, 3, 6–8]. The presence or absence of nuclear p53 expres-
sion, determined by immunohistochemistry, was highly
signiﬁcantly associated with the presence or absence of
TP53 aberrations. Signiﬁcant correlation between p53
expression, TP53 mutations, and TP53 locus LOH was
shown in other studies [1–3, 8]. In 13 cases with high p53
expression and/or LOH of chromosome 17p13 no TP53
mutations were detected. This may be the result of intra-
tumoral heterogeneity of TP53 gene mutations [36]o r
TP53 mutations escaping detection by our sequencing
method (especially in cases without detected LOH, prob-
ably because of admixture of normal DNA). Yet another
explanation may be that TP53 mutations were located
outside the investigated region of the gene (especially in
cases with LOH). In ten cases a single TP53 mutation was
detected without concomitant TP53 locus LOH. It may
well be that in these cases LOH was probably not identiﬁed
in the tumor DNA because of too much admixture of
normal DNA. In addition, TP53 LOH could be absent
because of the presence of a dominant-negative TP53
mutation in the tumors without concomitant loss of the
wild type allele. In ﬁve cases two TP53 mutations were
found and in all eight tumor samples from these cases no
LOH of the TP53 locus was observed, which is more
supportive of monoclonal tumor cell populations with bi-
allelic TP53 mutations than of dual clonality.
TP53 mutations are consistent during astrocytoma pro-
gression, because we demonstrate identical TP53 mutation
and TP53 locus LOH status in 21 of 27 investigated pairs
of primary tumor and recurrence, indicating clonal rela-
tionships between these tumor pairs. In two cases TP53
aberrations were found in the tumor recurrences only. It
may well be that the mutations were present in the ﬁrst
samples but not detected because the percentage of the
mutation-carrying tumor cells was too low. The fact that
in both primary tumors no TP53 LOH was observed and
only a low percentage of p53 positive cells was seen also
indicates the presence of many normal cells in these tumor
specimens. In four of 27 (15%) patients differences in
TP53 mutation and TP53 LOH between the primary
tumors and recurrences were unequivocally found. (One of
these cases, case 44, is illustrated in Fig. 1) Allelotyping
excluded tissue admixture in these cases. The differences
between the primary and recurrent tumors may well be the
result of intratumoral heterogeneity or alternatively, may
be indicative of two, clonally independent, tumors. Intra-
tumoral heterogeneity for TP53 aberrations has been
described previously for astrocytic brain tumors [36] and
in the setting of systemic metastasis of glioblastomas [37].
However, in a large study on 144 biopsies from 67
patients with recurrent astrocytoma no indication of in-
tratumoral heterogeneity was obtained [1]. In our study all
eight tumor samples from the four paired cases reliably
demonstrated TP53 locus LOH with loss of the reverse
alleles in three cases, indicating that the isolated DNA was
retrieved from a high percentage of clonal tumor cells with
little admixture of normal cells or tumor cells of another
clone. In addition, in cases 34 and 44 (Table 1) the TP53
mutation identiﬁed in the primary tumor was not found in
the recurrence and, vice versa, the mutation detected in the
recurrence was not present in the primary tumor. Because
TP53 mutation is an early event in astrocytoma tumori-
genesis the ﬁnding of different TP53 mutations in paired
primary tumor and recurrence is supportive for dual clo-
nality. Although intratumoral heterogeneity cannot be
excluded as the cause of different TP53 aberrations in the
paired primary tumors and recurrences, we believe our
results are more supportive for the presence of two,
clonally unrelated, entities in these four patients.
Thirteen of the 23 clonally related pairs of primary
tumor and recurrence demonstrated histologically con-
ﬁrmed malignant progression and all cases were consistent
with regard to TP53 aberrations (mutation, LOH and p53
expression). This result is in contrast with a study by Sarkar
et al. who reported increased p53 expression upon malig-
nant progression of astrocytic tumors. However, in that
study only p53 expression was determined and no TP53
mutation nor LOH analysis was performed. Comparable
with our study, no correlation between TP53 aberration and
interval to recurrence was found [38].
Correlation between MGMT promoter
hypermethylation and TP53 mutation
Methylation of the MGMT promoter, and thus absence of
AGT expression in gliomas reportedly correlates with
G:C[A:T transition mutations of TP53, in particular at
CpG sites [11, 21, 23–25]. The mechanism of the prefer-
ential occurrence of these mutations may be related to the
cytosine methylation-enhanced formation of adducts at
methylated CpG sites. A 5-methylcytosine adjacent to the
50 position of an O
6-methylated guanine strongly hampers
repair of this defect by AGT. Accordingly, inactivation of
MGMT gene expression causes retention of the methylated
adducts at the O
6 position of guanine. This results in
spontaneous or factor-mediated deamination which con-
verts the 5-methylcytosine into thymine. During DNA
replication thymine is incorporated and subsequently a G:C
to A:T transition mutation may originate at that spot. This
would support the relationship between epigenetic inacti-
vation of MGMT and accumulation of this mutation in
TP53 at CpG sites [23, 26].
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123Fig. 1 Combined analysis of
TP53 and MGMT, case 44
primary and second tumor.
a Diffuse astrocytoma (WHO
grade II); primary tumor (the
perinuclear halos are interpreted
as edema of the neuropilema
rather than an oligodendroglial
tumor component). b Diffuse
astrocytoma (WHO grade II);
second tumor.
c, d Immunohistochemistry for
p53 showing many positive
(brown) nuclei in both tumor
samples. e, f TP53 mutation
analysis: different mutations in
the primary and secondary
tumors, suggestive of the
presence of dual clonality.
g Loss of heterozygosity (LOH)
analysis showing loss of the
larger allele in the primary
tumor (microsatellite marker
D17S1866). h LOH analysis
showing loss of the shorter
allele in the second tumor
(reverse loss, indicative of dual
clonality). i MGMT promoter
hypermethylation analysis
(digested sample), both tumors
were not hypermethylated for
MGMT (MGMT digested/
MGMT undigested ratio of
MGMT2 probe\0.30)
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123In this study 90% of the G:C[A:T transition mutations
were located at CpG sites. However, we neither found a
signiﬁcant correlation between MGMT hypermethylation
and TP53 mutation, nor a correlation between MGMT
hypermethylation and speciﬁc TP53 G:C[A:T transition
mutations. Zawlik et al. found a signiﬁcantly higher fre-
quency of TP53 G:C[A:T transition mutations in MGMT
promoter hypermethylated glioblastomas, whereas the total
frequency of TP53 mutations in MGMT promoter hyper-
methylated and unmethylated glioblastomas was similar.
Interestingly, no association of MGMT promoter hyperme-
thylation and the accumulation of G:C[A:T transition
mutations in PTEN or other genes was found in that study
[26], suggesting speciﬁc involvement of the TP53 gene.
However, in colorectal tumorigenesis and gastric cancer
inactivation of MGMT by promoter hypermethylation
seemed to be associated with G[A mutations in K-ras [39–
41]. In accordance with our ﬁndings, Jesien-Lewandowicz
etal.recentlyreportednocorrelationbetweenmethylationof
the MGMT promoter and G:C[A:T TP53 mutations in a
series of 32 primary glioblastomas treated with radiotherapy
and surgery [42]. Future studies may reveal whether the
speciﬁc methylation of MGMT is representative of a gen-
eralizedstatusofgenomicmethylationandwhetherthereisa
gene-speciﬁcity of the G:C[A:T transition mutations.
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